Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Janux Therapeutics Inc banner

Janux Therapeutics Inc
NASDAQ:JANX

Watchlist Manager
Janux Therapeutics Inc Logo
Janux Therapeutics Inc
NASDAQ:JANX
Watchlist
Price: 13.16 USD 0.69%
Market Cap: $791.6m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

JANX Price Targets Summary
Janux Therapeutics Inc

Wall Street analysts forecast JANX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for JANX is 61.97 USD with a low forecast of 12.12 USD and a high forecast of 157.5 USD.

JANX Lowest Forecast
Wall Street Target
12.12 USD
-8% Downside
JANX Average Forecast
Wall Street Target
61.97 USD
371% Upside
JANX Highest Forecast
Wall Street Target
157.5 USD
1 097% Upside
Lowest
Price Target
12.12 USD
8% Downside
Average
Price Target
61.97 USD
371% Upside
Highest
Price Target
157.5 USD
1 097% Upside
Janux Therapeutics Inc Competitors:
Price Targets
RYI
Ryerson Holding Corp
-16% Downside
PTGX
Protagonist Therapeutics Inc
24% Upside
BTBT
Bit Digital Inc
203% Upside
OFIX
Orthofix Medical Inc
62% Upside
RYI
Ryerson Holding Corp
-16% Downside
PTGX
Protagonist Therapeutics Inc
24% Upside
BTBT
Bit Digital Inc
203% Upside
OFIX
Orthofix Medical Inc
62% Upside

Revenue
Forecast

N/A
Past Growth
42% / Year
Estimated Growth
Estimates Accuracy
27%
Average Beat
N/A
Past Growth
42% / Year
Estimated Growth
Estimates Accuracy
27%
Average Beat

The compound annual growth rate of Janux Therapeutics Inc's revenue for the next 4 years is 42%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss

What are analyst estimates?

See Also

Summary
JANX intrinsic value, competitors valuation, and company profile.
DCF Valuation
JANX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
JANX stock valuation using valuation multiples.
Wall Street Estimates
JANX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
JANX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is JANX's stock price target?
Price Target
61.97 USD

According to Wall Street analysts, the average 1-year price target for JANX is 61.97 USD with a low forecast of 12.12 USD and a high forecast of 157.5 USD.

What is Janux Therapeutics Inc's Revenue forecast?
Projected CAGR
42%

The compound annual growth rate of Janux Therapeutics Inc's revenue for the next 4 years is 42%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 316,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.